Skip to content

Ketamine research published in 2024

Page 21 of 26: studies 401 to 420 of 518, newest first. Back to the ketamine overview

Studies

A Comparison of the Efficacy and Adverse Effects of Ketamine and Electroconvulsive Therapy in the Management of Treatment-Resistant Depression: A Systematic Review.

Cureus March 1, 2024 Shaan I Chaudhri, Amina Amin, Binay K Panjiyar et al. 2 citations

Ketamine has been repeatedly demonstrated to be an effective treatment in the management of patients with treatment-resistant depression (TRD). An important question is whether it is equally or more effective than the current gold standard of electroconvulsive therapy (ECT), as the adverse effects of ECT can lead to memory loss and neurocognitive deficits. A literature search was conducted for...

DOI: 10.7759/cureus.55596 (opens in new tab) Full text (opens in new tab) Treatment of trd Treatment-resistant depression trd Therapy-resistant depression Refractory depression +4

Ketamine in Substance Use Disorder Treatment: A Narrative Review.

Alpha psychiatry March 1, 2024 Anna Famuła, Jakub Radoszewski, Tomasz Czerwiec et al. 8 citations

Substance use disorder (SUD) continues to pose a significant global health challenge, necessitating innovative and effective therapeutic interventions. Ketamine, traditionally recognized for its anesthetic properties, has emerged as a novel and promising avenue for the treatment of SUD. This narrative review critically examines the current body of literature surrounding the use of ketamine in...

DOI: 10.5152/alphapsychiatry.2024.241522 (opens in new tab) Full text (opens in new tab) Psychedelic therapy Alcohol dependence Addiction treatment Substance abuse recovery +1

Ketamine's rapid and sustained antidepressant effects are driven by distinct mechanisms.

Cellular and Molecular Life Sciences February 27, 2024 Radhika Rawat, Elif Tunc-Ozcan, Sara Dunlop et al. 17 citations

Administration of multiple subanesthetic doses of ketamine increases the duration of antidepressant effects relative to a single ketamine dose, but the mechanisms mediating this sustained effect are unclear. Here, we demonstrate that ketamine's rapid and sustained effects on affective behavior are mediated by separate and temporally distinct mechanisms. The rapid effects of a single dose of...

Are “mystical experiences” essential for antidepressant actions of ketamine and the classic psychedelics?

European Archives of Psychiatry and Clinical Neuroscience February 27, 2024 Kenji Hashimoto 51 citations

Abstract The growing interest in the rapid and sustained antidepressant effects of the dissociative anesthetic ketamine and classic psychedelics, such as psilocybin, is remarkable. However, both ketamine and psychedelics are known to induce acute mystical experiences; ketamine can cause dissociative symptoms such as out-of-body experience, while psychedelics typically bring about hallucinogenic...

Neurophysiological evidence that frontoparietal connectivity and GABA-A receptor changes underpin the antidepressant response to ketamine.

Translational Psychiatry February 24, 2024 Rachael Sumner, Rebecca McMillan, Anna Forsyth et al. 7 citations

Revealing the acute cortical pharmacodynamics of an antidepressant dose of ketamine in humans with depression is key to determining the specific mechanism(s) of action for alleviating symptoms. While the downstream effects are characterised by increases in plasticity and reductions in depressive symptoms-it is the acute response in the brain that triggers this cascade of events. Computational...

DOI: 10.1038/s41398-024-02738-w (opens in new tab) Full text (opens in new tab) Depression treatment Ketamine therapy Brain connectivity Psychopharmacology

Hippocampal volume changes after (R,S)-ketamine administration in patients with major depressive disorder and healthy volunteers.

Scientific Reports February 24, 2024 Jennifer W. Evans, Morgan C Graves, Allison C. Nugent et al. 9 citations

The hippocampus and amygdala have been implicated in the pathophysiology and treatment of major depressive disorder (MDD). Preclinical models suggest that stress-related changes in these regions can be reversed by antidepressants, including ketamine. Clinical studies have identified reduced volumes in MDD that are thought to be potentiated by early life stress and worsened by repeated...

The endogenous opioid system in the medial prefrontal cortex mediates ketamine's antidepressant-like actions.

Translational Psychiatry February 12, 2024 Cheng Jiang, Ralph Dileone, Christopher Pittenger et al. 37 citations

Recent studies have implicated the endogenous opioid system in the antidepressant actions of ketamine, but the underlying mechanisms remain unclear. We used a combination of pharmacological, behavioral, and molecular approaches in rats to test the contribution of the prefrontal endogenous opioid system to the antidepressant-like effects of a single dose of ketamine. Both the behavioral actions...

Microdosing ketamine in Drosophila does not block serotonin reuptake, but causes complex behavioral changes mediated by glutamate and serotonin receptors

Journal of Neurochemistry February 7, 2024 Kelly E. Dunham, Kani H. Khaled, Leah Weizman et al.

Microdosing ketamine is a novel antidepressant for treatment‐resistant depression. Traditional antidepressants, like selective serotonin reuptake inhibitors (SSRIs), inhibit serotonin reuptake, but it is not clear if ketamine shows a similar mechanism. Here, we tested the effects of feeding ketamine and SSRIs to Drosophila melanogaster larvae, which has a similar serotonin system to mammals and...

Efficacy of esketamine for the treatment of postpartum depression and pain control following cesarean section: a randomized, double-blind, controlled clinical trial

BMC Anesthesiology February 6, 2024 Shurong Li, Zhifang Zhuo, Renwei Li et al.

Background Postpartum depression (PPD) following a cesarean delivery is a frequently seen complication. Despite the prophylactic effects of ketamine, the impact of esketamine on PPD in women undergoing cesarean section remains uncertain. This study aimed to assess the effectiveness of esketamine as an adjunct to patient-controlled intravenous analgesia (PCIA) in preventing PPD in women...

Anhedonia in bipolar depression treated with ketamine

Bipolar Disorders February 4, 2024 Alina Wilkowska, Mariusz S. Wiglusz, Aleksandra Arciszewska et al. 17 citations

BACKGROUND: Bipolar depression is the major cause of morbidity in patients with bipolar disorder. It affects psychosocial functioning and markedly impairs occupational productivity. Anhedonia is one of the most debilitating symptoms of depression contributing to treatment resistance. It correlates with suicidality, low quality of life, social withdrawal, and poor treatment response. Currently,...

DOI: 10.1111/bdi.13409 (opens in new tab) Ketamine Anhedonia Depression economics Bipolar disorder +3

Anti-inflammatory effects of ketamine in the treatment-resistant depression: a narrative review

Farmacja Polska February 3, 2024 Marta Jóźwiak-Bębenista, Paulina Sokołowska, Edward Kowalczyk et al.

Przedmiot badań. U części pacjentów z depresją szczególnie nie odpowiadających na leczenie standardowymi lekami przeciwdepresyjnymi lub z myślami bądź próbami samobójczymi, stan zapalny jako źródło cytokin, przyczynia się do braku odpowiedzi na zastosowane terapie. Szansą dla takich osób jest terapia przy pomocy ketaminy. S-ketamina to szybko działający lek przeciwdepresyjny o wysokiej...

Sustained antidepressant effects of ketamine metabolite involve GABAergic inhibition-mediated molecular dynamics in aPVT glutamatergic neurons

Neuron February 1, 2024 Ayako Kawatake-Kuno, Haiyan Li, Hiromichi Inaba et al.

Summary Despite the rapid and sustained antidepressant effects of ketamine and its metabolites, their underlying cellular and molecular mechanisms are not fully understood. Here, we demonstrate that the sustained antidepressant-like behavioral effects of (2S,6S)-hydroxynorketamine (HNK) in repeatedly stressed animal models involve neurobiological changes in the anterior paraventricular nucleus...

Efficacy and safety of ketamine and esketamine for unipolar and bipolar depression: an overview of systematic reviews with meta-analysis

Frontiers in Psychiatry February 1, 2024 Alessandro Rodolico, Pierfelice Cutrufelli, Antonio Di Francesco et al. 28 citations

Background Unipolar and bipolar depression present treatment challenges, with patients sometimes showing limited or no response to standard medications. Ketamine and its enantiomer, esketamine, offer promising alternative treatments that can quickly relieve suicidal thoughts. This Overview of Reviews (OoR) analyzed and synthesized systematic reviews (SRs) with meta-analysis on randomized...

Ensuring the affordable becomes accessible-lessons from ketamine, a new treatment for severe depression.

Australian & New Zealand Journal of Psychiatry February 1, 2024 Anthony Rodgers, Dilara Bahceci, Christopher G. Davey et al. 8 citations

In this paper, the case study of ketamine as a new treatment for severe depression is used to outline the challenges of repurposing established medicines and we suggest potential solutions. The antidepressant effects of generic racemic ketamine were identified over 20 years ago, but there were insufficient incentives for commercial entities to pursue its registration, or support for...

Ketamine-assisted psychotherapy, psychedelic methodologies, and the impregnable value of the subjective—a new and evolving approach

Frontiers in Psychiatry February 1, 2024 Phil Wolfson, Gita Vaid 17 citations

Psychiatry is in a growth phase in which several psychedelic medicines have entered its arena with great promise. Of these, presently, ketamine is the only medicine that may be legally prescribed. We hypothesize that at subanesthetic doses, ketamine produces a unique spectrum of altered states, ranging from psychoactive to deep ego-dissolving experiences, that are intrinsic to ketamine’s...

Unique Effects of (R)-Ketamine Compared to (S)-Ketamine on EEG Theta Power in Rats.

Pharmaceuticals February 1, 2024 Dóra Pothorszki, Szabolcs Koncz, Dóra Török et al. 7 citations

Differences in the pharmacological effects of (S)-ketamine and (R)-ketamine are at the focus of research. Clinical data and our rat studies confirmed the antidepressant effect of (S)- but not (R)-ketamine, with similar differences in quantitative electroencephalogram (EEG) and sleep effects. In contrast, studies mainly on mice showed some stronger, preferable effects of (R)-ketamine. EEG theta...

Ketamine in Chronic Pain: A Review.

Cureus February 1, 2024 Ana Faísco, Rita Dinis, Tânia Seixas et al. 8 citations

Ketamine has been used in the treatment of several pain syndromes, particularly those with a relevant neuropathic component. Sub-anesthetic doses of ketamine produce a potent analgesic effect, due to its inhibition of N-methyl-D-aspartate receptors and enhancement of descending inhibitory pathways. Its short-term analgesic effect is well-documented perioperatively, with an associated reduction...

DOI: 10.7759/cureus.53365 (opens in new tab) Full text (opens in new tab) Cancer pain Chronic postoperative pain Non-oncological pain Ketamine therapy +4

The impact of ketamine on outcomes in critically ill patients: a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials.

Acute and critical care February 1, 2024 Yerkin G Abdildin, Karina Tapinova, Assel Nemerenova et al. 9 citations

This meta-analysis aims to evaluate the effects of ketamine in critically ill intensive care unit (ICU) patients. We searched for randomized controlled trials (RCTs) in PubMed, Scopus, and the Cochrane Library; the search was performed initially in January but was repeated in December of 2023. We focused on ICU patients of any age. We included studies that compared ketamine with other...

DOI: 10.4266/acc.2023.00829 (opens in new tab) Full text (opens in new tab) Critical care Critical illness Intensive care unit Pain management analgesia +5

Exploring Esketamine's Therapeutic Outcomes as an FDA-Designated Breakthrough for Treatment-Resistant Depression and Major Depressive Disorder With Suicidal Intent: A Narrative Review.

Cureus February 1, 2024 Suneeta Kumari, Hassan A Chaudhry, Adam Sagot et al. 13 citations

The expansive spectrum of major depressive disorder (MDD) continues to pose challenges for psychiatrists to treat effectively. Oral antidepressant (OAD) medications that alter monoamine neurotransmitters, mainly selective serotonin reuptake inhibitors (SSRIs) and selective norepinephrine reuptake inhibitors (SNRIs), have been the mainstay of therapy for decades. Although these drugs have been...

DOI: 10.7759/cureus.53987 (opens in new tab) Full text (opens in new tab) Treatment-resistant depression FDA Approval Nmda receptor antagonist Placebo controlled trials +6

Effectiveness of Ketamine for the Treatment of Post-Traumatic Stress Disorder - A Systematic Review and Meta-Analysis.

Clinical neuropsychiatry February 1, 2024 Thales Marcon Almeida, Ursula Raianny Lacerda da Silva, Jeully Pereira Pires et al. 20 citations

Post-traumatic stress disorder (PTSD) is an enduring condition characterized by a chronic course and impairments across several areas. Despite its significance, treatment options remain limited, and remission rates are often low. Ketamine has demonstrated antidepressant properties and appears to be a promising agent in the management of PTSD. A systematic review was conducted in PubMed/MEDLINE,...